Vertigo News and Research

Latest Vertigo News and Research

Study finds sharp increase in CT scan use in ED between 1996-2007

A review of national data from 1996 through 2007 reveals a sharp uptick in the use of computed tomography, or CT, scans to diagnose illnesses in emergency departments, a University of Michigan Health System study finds.

11 Aug 2011

Current prevention strategies may not be very effective at reducing in-hospital falls

While falls are a common cause of injury, particularly in older, hospitalized patients, some may not be as preventable as once thought. According to a new literature review published in the Journal of the American Academy of Orthopaedic Surgeons, many of the risks that frequently cause falls are not adequately addressed with the fall prevention initiatives used in healthcare facilities.

7 Jul 2011

EMA CHMP issues positive opinion for Baxter's IVIG therapy for multifocal motor neuropathy

Baxter International Inc. announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for extension of the therapeutic indications of KIOVIG to include a new indication for multifocal motor neuropathy (MMN), a severe, debilitating disorder requiring lifelong treatment.

From Baxter International Inc. 24 Jun 2011

Endo's complete response for new formulation of OPANA ER NDA accepted by the FDA

Endo Pharmaceuticals announced today that it received notification from the U.S. Food and Drug Administration (FDA) that Endo's complete response to the FDA's Jan. 7, 2011 Action Letter relating to Endo's new drug application (NDA) for a new formulation of OPANA ER has been accepted.

24 Jun 2011

FDA approves Valeant's Potiga Tablets for treatment of partial-onset seizures

Valeant Pharmaceuticals International, Inc. and GlaxoSmithKline announced today that the U.S. Food and Drug Administration (FDA) has approved Potiga Tablets, a potassium channel opener, as adjunctive treatment of partial-onset seizures in patients aged 18 years and older.

13 Jun 2011

AstraZeneca receives FDA approval for NEXIUM I.V. to treat GERD with erosive esophagitis

AstraZeneca announced today that the U.S. Food and Drug Administration has approved the use of NEXIUM I.V. for Injection for children ages greater than 1 month old for the short-term treatment of gastroesophageal reflux disease with erosive esophagitis when oral therapy is not possible or appropriate.

3 May 2011

Study shows direct link between cotton swab use and ruptured eardrum

A study by Henry Ford Hospital shows a direct association between cotton swab use and ruptured eardrum. The study also shows that in most cases the rupture heals on its own and surgery is only necessary for the most severe cases.

28 Apr 2011

Positive results from Otonomy's OTO-104 Phase 1b study in Meniere's disease

Otonomy, Inc., a clinical stage biopharmaceutical company developing innovative therapeutics for diseases and disorders of the inner and middle ear, today announced positive data from a Phase 1b study of the company's lead product candidate, OTO-104, in patients with Meniere's disease.

28 Apr 2011

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced results from several new data analyses from the pivotal Phase III studies evaluating the addition of its investigational oral protease inhibitor VICTRELIS to peginterferon alfa-2b and ribavirin in adult patients with chronic hepatitis C virus genotype 1 infection.

1 Apr 2011

EC grants marketing authorization for GSK, Valeant's Trobalt to treat epilepsy

GlaxoSmithKline and Valeant Pharmaceuticals International, Inc. announced today that the European Commission has granted marketing authorisation for Trobalt as an adjunctive treatment of partial onset seizures, with or without secondary generalisation in adults aged 18 years and above with epilepsy.

30 Mar 2011

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced that several new data analyses from Phase III studies of VICTRELIS, its investigational oral hepatitis C protease inhibitor, will be presented at The International Liver CongressTM / 46th European Association for the Study of the Liver annual meeting.

9 Mar 2011

Endolymphatic sac shunt surgery improved hearing loss symptoms in flight attendant

When fluctuating hearing loss, with frequent bouts of nausea and vertigo caused New York flight attendant Patricia Gilbert to miss several work shifts, she sought answers from the medical community.

4 Mar 2011

State court jury rules in favor of Merck in FOSAMAX trial

Merck & Co., Inc. today said a state court jury in New Jersey found in its favor in the Rosenberg v. Merck case, rejecting the claims of a woman who blamed her dental and jaw related problems on her FOSAMAX use.

15 Feb 2011

Early MRI in young adults associated with lower rate of stroke misdiagnosis

While the American Stroke Association reports that stroke is the third leading cause of death and one of the top causes of disability in the United States, young adults showing signs of suffering a stroke are sometimes misdiagnosed in hospital emergency rooms, preventing them from receiving early effective treatment that can prevent serious damage.

11 Feb 2011

Zogenix receives 2011 DDP Industry Achievement Award for SUMAVEL DosePro

Zogenix, Inc. today announced that it has received the 2011 Drug Delivery Partnerships™ ("DDP") Innovation Award in the Industry Achievement category for SUMAVEL DosePro (sumatriptan injection) Needle-free Delivery System.

9 Feb 2011

Adjunctive lacosamide reduces seizures and improves responder rates

Comprehensive analyses of pooled data from three randomized, double-blind, placebo-controlled Phase II/III trials showing the efficacy and tolerability of Vimpat® (lacosamide) C-V for patients with partial-onset seizures, regardless of the type of concomitant AED used, have been published in the drug evaluation journal, CNS Drugs.

13 Jan 2011

Zogenix's SUMAVEL DosePro Needle-free Delivery System wins 2010 Most Innovative Product award

Zogenix, Inc. today announced that CONNECT, a regional San Diego nonprofit organization, selected SUMAVEL® DosePro™ (sumatriptan injection) Needle-free Delivery System as a 2010 Most Innovative Product (MIP) winner at the MIP Awards Luncheon on December 10, 2010.

13 Dec 2010

Zometa improves OS, PFS in newly diagnosed multiple myeloma patients: Phase III study

A newly published study in the Lancet suggested that a first-line treatment regimen including Zometa (zoledronic acid) significantly improved overall survival and progression-free survival in newly diagnosed multiple myeloma patients compared with a regimen that included oral clodronate. The impact on survival was independent of the effect of Zometa on bone complications (also known as skeletal-related events or SREs).

4 Dec 2010

Denmark grants marketing authorization for SUMAVEL DosePro Needle-Free Delivery System

Zogenix, Inc. and Desitin Pharmaceuticals GmbH today announced that the Danish Medicines Agency of Denmark has approved the Marketing Authorization Application (MAA) for SUMAVEL® DosePro™ (sumatriptan injection) Needle-Free Delivery System. Denmark is the first country in Europe to grant marketing authorization for SUMAVEL DosePro for the acute treatment of migraine attacks, with or without aura, and the acute treatment of cluster headache.

2 Dec 2010

Long-term phase 3 trial confirms safety of lubiprostone in Japanese patients with chronic idiopathic constipation

Sucampo Pharmaceuticals, Inc. and Abbott today announced positive top-line data from a 48-week phase 3 long-term safety and efficacy clinical trial of lubiprostone in Japanese patients with chronic idiopathic constipation (CIC). The trial demonstrated that lubiprostone was safe and well-tolerated.

30 Nov 2010

Vertigo News and Research

Latest Vertigo News and Research

Study finds sharp increase in CT scan use in ED between 1996-2007

Current prevention strategies may not be very effective at reducing in-hospital falls

EMA CHMP issues positive opinion for Baxter's IVIG therapy for multifocal motor neuropathy

Endo's complete response for new formulation of OPANA ER NDA accepted by the FDA

FDA approves Valeant's Potiga Tablets for treatment of partial-onset seizures

AstraZeneca receives FDA approval for NEXIUM I.V. to treat GERD with erosive esophagitis

Study shows direct link between cotton swab use and ruptured eardrum

Positive results from Otonomy's OTO-104 Phase 1b study in Meniere's disease

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

EC grants marketing authorization for GSK, Valeant's Trobalt to treat epilepsy

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Endolymphatic sac shunt surgery improved hearing loss symptoms in flight attendant

State court jury rules in favor of Merck in FOSAMAX trial

Early MRI in young adults associated with lower rate of stroke misdiagnosis

Zogenix receives 2011 DDP Industry Achievement Award for SUMAVEL DosePro

Adjunctive lacosamide reduces seizures and improves responder rates

Zogenix's SUMAVEL DosePro Needle-free Delivery System wins 2010 Most Innovative Product award

Zometa improves OS, PFS in newly diagnosed multiple myeloma patients: Phase III study

Denmark grants marketing authorization for SUMAVEL DosePro Needle-Free Delivery System

Long-term phase 3 trial confirms safety of lubiprostone in Japanese patients with chronic idiopathic constipation

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Vertigo News and Research

Latest Vertigo News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in